Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Appel

Showing results (441-450 of 455) with videos related to

Pageof 46
Sort By:
Annals of Neurology|May 9, 2017
Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutationsDale J Lange, Mona Shahbazi, Vincenzo Silani, et al.
Brain : a Journal of Neurology|April 7, 2021
Neuroinflammation is highest in areas of disease progression in semantic dementiaBelen Pascual, Quentin Funk, Paolo Zanotti-Fregonara, et al.
Neurology|May 20, 2009
SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophyM C Hannibal, E K Ruzzo, L R Miller, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Alzheimer'S Research & Therapy|July 4, 2025
Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trialAlireza Faridar, Nazaret Gamez, Daling Li, et al.
The Lancet. Neurology|April 2, 2013
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man studyTimothy M Miller, Alan Pestronk, William David, et al.
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|September 27, 2005
Promoting excellence in end-of-life care in ALSHiroshi Mitsumoto, Mark Bromberg, Wendy Johnston, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
Neurology|August 27, 2003
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisM E Cudkowicz, J M Shefner, D A Schoenfeld, et al.
Pageof 46

Showing results (441-450 of 455) with videos related to

Sort By:
Pageof 46
Annals of Neurology|May 9, 2017
Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutationsDale J Lange, Mona Shahbazi, Vincenzo Silani, et al.
Brain : a Journal of Neurology|April 7, 2021
Neuroinflammation is highest in areas of disease progression in semantic dementiaBelen Pascual, Quentin Funk, Paolo Zanotti-Fregonara, et al.
Neurology|May 20, 2009
SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophyM C Hannibal, E K Ruzzo, L R Miller, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Alzheimer'S Research & Therapy|July 4, 2025
Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trialAlireza Faridar, Nazaret Gamez, Daling Li, et al.
The Lancet. Neurology|April 2, 2013
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man studyTimothy M Miller, Alan Pestronk, William David, et al.
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|September 27, 2005
Promoting excellence in end-of-life care in ALSHiroshi Mitsumoto, Mark Bromberg, Wendy Johnston, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
Neurology|August 27, 2003
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisM E Cudkowicz, J M Shefner, D A Schoenfeld, et al.
Pageof 46